ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: INFO11-SA

Cure Glomerulonephropathy Network (CureGN)

Session Information

  • Informational Posters - III
    November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Nestor, Jordan Gabriela, Columbia University, New York, New York, United States
  • D'Alessandri-Silva, Cynthia J., Connecticut Children's Medical Center, Hartford, Connecticut, United States
  • Mansfield, Sarah, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Helmuth, Margaret, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Wang, Chia- Shi, Emory University, Atlanta, Georgia, United States
  • Ahn, Wooin, Columbia University, New York, New York, United States
  • Zee, Jarcy, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Glenn, Dorey A., University of North Carolina, Chapel Hill, North Carolina, United States
Background

CureGN is a multi-center, prospective observational study of glomerular disease funded by the NIH-NIDDK. To date, CureGN has enrolled 2322 of 2400 children and adults with biopsy-proven minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or IgA nephropathy/vasculitis (IgAN/IgAV) from 70 sites in the USA, Canada, Italy, and Poland.

Methods

Patients with a diagnostic kidney biopsy within 5 years are eligible to participate. Exclusion criteria include end-stage kidney disease (ESKD) at enrollment and glomerular disease attributed to a secondary cause. Visits are conducted 3 times/year, with one mandatory annual in-person visit. In addition to clinical and patient-reported outcomes, biospecimens are collected, as well as outcomes of ESKD, death, and non-renal complications (e.g., infection, malignancy, cardiovascular and thromboembolic events). CureGN supports clinical and translational research by combining detailed clinical data with a biorepository of DNA, RNA, blood, and urine specimens as well as a Digital Pathology Repository (DPR) of biopsy images to provide a shared tool for investigators.

Results

Enrollment began 12/2014. The consortium has maintained a participant retention rate of 84% over a median follow-up of 2.1 years. Participant demographic and outcome data as of March 2019 are shown in Table 1. To date, 896 (39%) cases in the DPR have been scanned and digitally archived and are being scored.

Conclusion

The study objectives support a variety of approaches to identify mechanistically distinct subgroups, define accurate biomarkers of disease activity, delineate disease-specific treatment targets and inform future therapeutic trials to advance the diagnosis, care, and outcomes of glomerular disease. A total of 4 publications, presenting baseline descrriptive data, and 13 ancillaries studies have emerged from this initiative.

Funding

  • NIDDK Support